BCIwiki (bciwiki.com) — In an industry analysis published on August 12, 2026, Neurotech Reports examined uneven funding across neurotechnology. Author Sharena Rice cited transactions including Neuralink’s $650 million Series E in June 2025 to argue that large rounds can lift aggregate totals without indicating broadly easier access to capital for startups.
The article considers large rounds for a few technology platforms alongside expansion in care delivery. A July 2026 Science Corporation appointment announcement also cited its $230 million Series C earlier that year, consistent with Rice’s example. That transaction and Neuralink’s round occurred at different times and should not be presented as a single new financing event.
Rice points to treatment networks including Ascendia Autism Care and HOPE Therapeutics when discussing investment in billable care delivery. These are financing and service-expansion examples, not clinical efficacy findings for BCI devices.
The author argues that device developers progressing from prototypes toward first-in-human studies and regulatory clearance face selective private investment and uncertainty around nondilutive support. The article notes that specific award totals for the next NIH Blueprint MedTech cycle were not public. A narrower financing path is the author’s interpretation, not a disclosed program cut or a verified funding forecast for individual companies.